Patents Assigned to Chugai Seiyaku Kabushiki Kaisha
  • PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSE
    Publication number: 20220378800
    Abstract: An improved solubility of a pharmaceutical composition or formulation containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or a salt thereof can be achieved by forming granules of the compound or salt thereof and allowing the granules to be present together with a disintegrating agent.
    Type: Application
    Filed: July 29, 2022
    Publication date: December 1, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takashi TOMIMATSU, Kensuke OKAZAKI, Yumi OGAWA, Takahiro YAMAMURA
  • METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN
    Publication number: 20220380827
    Abstract: Herein is reported a method for the production of an immunoglobulin comprising the following steps: a) providing a eukaryotic cell comprising a nucleic acid encoding the immunoglobulin, b) cultivating the eukaryotic cell in a cultivation medium wherein the amount of glucose available in the cultivation medium per time unit is kept constant and limited to less than 80% of the amount that could maximally be utilized by the cells in the cultivation medium per time unit, and c) recovering the immunoglobulin from the culture.
    Type: Application
    Filed: August 4, 2022
    Publication date: December 1, 2022
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Reinhard Franze, Chikashi Hirashima, Thomas Link, Yoshinori Takagi, Shinya Takuma, Yuriko Tsuda
  • Hyaluronic acid derivative modified with polyethylene glycol
    Patent number: 11512147
    Abstract: The present invention provides hyaluronic acid derivatives including one or more of each of repeating units represented by the formulae (Ia), (Ib), and (Ic) in which certain cationic sites, certain hydrophobic sites, and certain hydrophilic sites have been introduced. In addition, the present invention provides complexes of the hyaluronic acid derivatives with a drug and pharmaceutical compositions including the hyaluronic acid derivatives, in particular, complexes of the hyaluronic acid derivatives with a drug.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 29, 2022
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kazuo Hattori, Takashi Nakai, Teruo Nakamura, Tsuyoshi Shimoboji
  • METHOD FOR PRODUCING TETRACYCLIC COMPOUND
    Publication number: 20220372025
    Abstract: This invention relates to a method for manufacturing 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, and is industrially preferable, allowing an objective substance to be obtained in high yield more safely and easily than the conventional method.
    Type: Application
    Filed: September 3, 2019
    Publication date: November 24, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroki SERIZAWA, Akira KAWASE, Hiroshi FUKUDA, Naoto HAMA
  • T cell-redirected antigen-binding molecule for cells having immunosuppression function
    Patent number: 11505605
    Abstract: It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 22, 2022
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Osaka University
    Inventors: Tomoyuki Igawa, Takahiro Ishiguro, Shimon Sakaguchi, Hiroyoshi Nishikawa
  • Method for producing peptide, and method for processing bases
    Patent number: 11492369
    Abstract: It was found that a salt formed of an acid and a base having characteristics set forth below can inactivate a deprotecting agent, thereby suppressing redundant peptide elongation: (i) the base is different in type from a base used as a deprotecting agent, and (ii) a conjugate acid of the base has a pKa smaller than that of a conjugate acid of a base used as a deprotecting agent.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: November 8, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kenichi Nomura, Ryuichi Takeyama
  • Immunoactivating antigen-binding molecule
    Patent number: 11485790
    Abstract: It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a T cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: November 1, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Taro Miyazaki, Kenji Taniguchi, Naoka Hironiwa
  • ANTIBODY CLEAVAGE SITE BINDING MOLECULE
    Publication number: 20220324975
    Abstract: The present disclosure provides a pharmaceutical composition comprising an antibody having ADCC activity, a T cell-redirecting antibody, or a cell expressing a chimeric receptor, for use in combination with the administration of an antigen binding molecule capable of binding to a target antigen, wherein the primary molecule comprises a linker that is cleaved by protease, the antigen binding molecule obtained through the cleavage of the linker has the ability to bind to the target antigen, variable regions of the antibody having ADCC activity or the T cell-redirecting antibody, and an extracellular binding domain of the chimeric receptor bind to a cell expressing the target antigen via binding to the antigen binding molecule resulting from the cleavage of the cleavable linker.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 13, 2022
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Yamaguchi University
    Inventors: Mika Sakurai, Tomoyuki Igawa, Yasunori Komori, Koji Tamada, Yukimi Sakoda
  • PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII
    Publication number: 20220324999
    Abstract: The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.
    Type: Application
    Filed: June 27, 2022
    Publication date: October 13, 2022
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventor: Koichiro Yoneyama
  • METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND/OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND/OR ACTIVATED COAGULATION FACTOR X
    Publication number: 20220315667
    Abstract: An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
    Type: Application
    Filed: May 31, 2022
    Publication date: October 6, 2022
    Applicants: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche AG
    Inventors: Koichiro Yoneyama, Christophe Schmitt
  • PHARMACEUTICAL COMPOSITION WHICH CAN BE USED FOR PREVENTION AND/OR TREATMENT OF ACQUIRED HEMOPHILIA A, AND PRODUCT COMPRISING SAID PHARMACEUTICAL COMPOSITION
    Publication number: 20220305122
    Abstract: The present inventors discovered that administration of a pharmaceutical composition comprising emicizumab according to a predetermined administration regimen has the potential to effectively prevent and/or treat acquired hemophilia A.
    Type: Application
    Filed: October 8, 2020
    Publication date: September 29, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Koichiro Yoneyama, Sayaka Nagami
  • TETRACYCLIC COMPOUND
    Publication number: 20220306578
    Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).
    Type: Application
    Filed: April 29, 2020
    Publication date: September 29, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kazutomo KINOSHITA, Kohsuke ASOH, Noriyuki FURUICHI, Toshiya ITO, Hatsuo KAWADA, Nobuya ISHII, Hiroshi SAKAMOTO, WooSang HONG, MinJeong PARK, Yoshiyuki ONO, Yasuharu KATO, Kenji MORIKAMI, Takashi EMURA, Nobuhiro OIKAWA
  • ANTIBODY MOLECULES
    Publication number: 20220306755
    Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
    Type: Application
    Filed: June 1, 2022
    Publication date: September 29, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Mika Sakurai, Tetsuo Kojima, Tatsuhiko Tachibana, Hirotake Shiraiwa, Hiroyuki Tsunoda, Yoshinobu Higuchi
  • Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
    Patent number: 11454633
    Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: September 27, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshinao Ruike, Taichi Kuramochi, Hiroyasu Muramatsu, Atsunori Ueyama, Tomoyuki Igawa, Hitoshi Katada, Yuji Hori
  • METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN
    Publication number: 20220282298
    Abstract: Herein is reported a method for the production of an immunoglobulin comprising the following steps: a) providing a eukaryotic cell comprising a nucleic acid encoding the immunoglobulin, b) cultivating the eukaryotic cell in a cultivation medium wherein the amount of glucose available in the cultivation medium per time unit is kept constant and limited to less than 80% of the amount that could maximally be utilized by the cells in the cultivation medium per time unit, and c) recovering the immunoglobulin from the culture.
    Type: Application
    Filed: May 24, 2022
    Publication date: September 8, 2022
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Reinhard Franze, Chikashi Hirashima, Thomas Link, Yoshinori Takagi, Shinya Takuma, Yuriko Tsuda
  • SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
    Publication number: 20220280532
    Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Application
    Filed: May 9, 2022
    Publication date: September 8, 2022
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Xiaoping Zhang, Kimio Terao
  • Preparation containing tetracyclic compound at high dose
    Patent number: 11433076
    Abstract: An improved solubility of a pharmaceutical composition or formulation containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or a salt thereof can be achieved by forming granules of the compound or salt thereof and allowing the granules to be present together with a disintegrating agent.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 6, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takashi Tomimatsu, Kensuke Okazaki, Yumi Ogawa, Takahiro Yamamura
  • ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
    Publication number: 20220275076
    Abstract: The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue.
    Type: Application
    Filed: May 12, 2022
    Publication date: September 1, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshinao RUIKE, Taichi KURAMOCHI
  • METHODS FOR PRODUCING POLYPEPTIDES BY REGULATING POLYPEPTIDE ASSOCIATION
    Publication number: 20220267822
    Abstract: In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. For example, the present invention can be suitably applied to the preparation of bispecific antibodies.
    Type: Application
    Filed: November 5, 2021
    Publication date: August 25, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda
  • MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII
    Publication number: 20220267470
    Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor DC/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 25, 2022
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi